Stroke Research and Treatment / 2018 / Article / Tab 3

Clinical Study

Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study

Table 3

Secondary endpoint-a occurrences (all cardiovascular events, SBIs and adverse events).

ASA n=36controls n=47

n (%)n (%)p-value (Chi-Square)
Non-fatal stroke1 (2.8)1 (2.1)0.331
TIA-1 (2.1)
New SBIs1 (2.8)6 (12.8)
Non-fatal MI2 (5.6)1 (2.1)
CV mortality-1 (2.1)
Gastrointestinal adverse events2 (5.6)1 (2.1)
Epistaxis-1 (2.1)
Other causes of mortality--
No events30 (83.3)35 (74.5)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.